Blue Earth moves toward U.K. prostate radiopharmaceutical licensing

2017 01 26 12 32 44 153 Check Mark 400

Blue Earth Therapeutics has secured an "innovation passport" from the U.K.'s Innovative Licensing and Access Pathway (ILAP) for its investigational therapeutic radiopharmaceutical lutetium-177 (Lu-177) rhPSMA-10.1 for treatment of metastatic prostate cancer.

The passport is the entry point to ILAP's process of accelerating time to market for investigational devices. ILAP coordinates a company's interaction with the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and the process of submitting marketing authorization applications, Blue Earth said.

Page 1 of 114
Next Page